Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17 USD | -6.85% | -7.15% | +181.92% |
Financials (USD)
Sales 2024 * | 2.5M | Sales 2025 * | - | Capitalization | 710M |
---|---|---|---|---|---|
Net income 2024 * | -73M | Net income 2025 * | -104M | EV / Sales 2024 * | 200 x |
Net cash position 2024 * | 210M | Net cash position 2025 * | 263M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.61
x | P/E ratio 2025 * |
-6.88
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.19% |
Latest transcript on Longboard Pharmaceuticals, Inc.
1 day | -6.85% | ||
1 week | -7.15% | ||
Current month | -21.30% | ||
1 month | -16.99% | ||
3 months | -27.54% | ||
6 months | +223.19% | ||
Current year | +181.92% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 20-01-02 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 20-12-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 20-11-30 |
Director/Board Member | 68 | 20-11-30 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.41% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +1.25% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 17 | -6.85% | 628,046 |
24-04-16 | 18.25 | 0.00% | 281,291 |
24-04-15 | 18.25 | -4.95% | 448,449 |
24-04-12 | 19.2 | -6.11% | 547,013 |
24-04-11 | 20.45 | +11.69% | 591,405 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+181.92% | 710M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- LBPH Stock